Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
We retrospectively reviewed 134 patients to evaluate atazanavir-related bilirubin elevation as an adherence marker. Using a 2 log reduction or undetectable viral load as a marker for suppression, the median bilirubin increase at first follow-up was 1.3 (0.7-2.2), versus 0.2 (-0.05-0.65) for those not suppressed. An increase in bilirubin of more than 0.4 mg/dl correctly classified 81% of patients as having successful treatment response (sensitivity 87%, specificity 63%), suggesting that bilirubin is a good adherence marker.
Petersen
Kyle
K
National Naval Medical Center, Bethesda, MD, USA.
Riddle
Mark S
MS
Jones
Lindsay E
LE
Furtek
Kari J
KJ
Christensen
Anne R
AR
Tasker
Sybil A
SA
Hale
Braden R
BR
D000328:Adult; D000069446:Atazanavir Sulfate; D001663:Bilirubin / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D010349:Patient Compliance; D011725:Pyridines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D019562:Viral Load
D015415:Biomarkers; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D001663:Bilirubin